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Abstract The aims of this work are to study the antitumor
effect of the adeno-associated virus on the xenografted tumors
of chick embryo chorioallantoic membrane and predict poten-
tial genes and biological pathways which are associated with
renal cell carcinoma. The adeno-associated virus NT4-TAT-6×
His-VHLbeta was constructed and identified. Then, chick em-
bryos with xenografted tumor were divided into three groups
and respectively inoculated with rAAV/NT4-TAT-6×His-
VHLbeta (group A), empty virus (group B), and phosphate-
buffered saline (group C, the control subject). Antitumor effect
in each group was investigated by means of immunofluores-
cence observation. Genes interacted with von Hippel–Lindau
were screened by Search Tool for the Retrieval of Interacting
Genes/Proteins database, while pathway analysis were per-
formed based on Kyoto Encyclopedia of Genes and Genomes.
The growth of xenografted tumors inoculated with recombinant
adeno-associated virus was slower than the control subjects.
The tumor volumes of group A showed significant difference
compared with group B and group C (P<0.05). Growth of
xenografted tumors which administered with the recombinant
adeno-associated virus was inhibited. Among the protein–pro-
tein interaction network, TCEB2, HIF1A, TCEB1, CUL2,
RBX1, and PHF17 were hub genes which might be involved
in the development of renal cell carcinoma. The most signifi-
cant signaling pathway was renal cell carcinoma. In this paper,
we constructed and identified the recombinant adeno-
associated virus NT4-TAT-6×His-VHLbeta and studied the
antitumor effect of the adeno-associated virus on xenografted
tumors of chicken embryo chorioallantoic membrane. In addi-
tion, genes in the protein–protein interaction network which are
associated with renal cell carcinoma were revealed and the
biological pathway of renal cell carcinoma was identified.
Our results provide a gene-therapeutic agent for the treatment
of human renal cell carcinoma.
Keywords Renal cell carcinoma . Recombinant
adeno-associated virus . VonHippel–Lindau . Protein–protein
interaction network . Pathway enrichment analysis
Introduction
Renal cell carcinoma (RCC) is inherently resistant to cytotox-
in, hormone, conventional chemotherapy, and radiotherapy
[1–3]. Although the response rates of immunotherapeutic
and molecular targeting agents are acceptable, their long-
term survival benefits remain limited [4]. Approximately
30 %percent of RCC patients develop metastasis [5]. Recent-
ly, treatment for patients with metastatic RCC has shifted from
conventional cytokines to the angiogenesis inhibitors [6].
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Currently, the recombinant adeno-associated virus has been
commonly used as a vehicle for delivering therapeutic DNA.
This delivery vehicle has the advantages of nonpathogenic
nature, broad host range, ability to infect both dividing and
nondividing cells, and stabilized expression of transfected
genes [7]. Recently, there are many studies on gene expression
analysis of RCC.Morris et al. [8] identified tumor methylation
of SCUBE3 was associated with a significantly increased risk
of cancer death or relapse. While Varela [9] sequenced the
protein-coding exome in a series of primary clear cell RCC
(ccRCC) and identified the SWI/SNF chromatin remodeling
complex gene PBRM1 as a secondmajor gene of ccRCC [10].
Plasmid pBV220-NT4 is a stable and effective vector,
which is commonly used as a vehicle for transmitting expres-
sion genes. Xi Bao [11] investigated survivin as an anticancer
therapeutic target by use of PBV220-NT4 vector. The expres-
sion gene of Ant-Shepherdin[79-87] was inserted in PBV220-
NT4 vector, and afterward, the gene was sub-cloned into the
shuttle plasmid of adeno-associated virus. Zheng et al. [12]
inserted NT4-NAP gene into pBV220 to produce a recombi-
nant pBV220-NT4-NAP and transfected it into mammalian
retina cells with constant NAP production. The NAP produc-
tion maintained its biological neuroprotective activities.
Several studies have demonstrated the importance of the
von Hippel–Lindau (VHL) gene on inhibiting RCC growth.
For example, Lisztwan et al. [13] highlighted that pVHL, the
product of the VHL gene, plays an important role in the
regulation of cell growth and differentiation of human renal
cells. Inactivation of the VHL gene was the frequent genetic
event in human RCC and linked to the hereditary VHL disease
and sporadic ccRCC [13, 14]. The inactivation of VHL gene
predisposed affect individuals to VHL syndrome and was an
early genetic event associated with sporadic RCC and CNS
hemangioblastomas [15].
Function of pVHL related to its ability to target specific
proteins for destruction. The stable complexes of pVHL
contained other proteins called Elongin B (TCEB2), Elongin
C (TCEB1), Cul2, and Rbx1 [16–18]. These complexes were
capable of directing the covalent attachment of polyubiquitin
tails to specific proteins, which served as signals for such
proteins to be degraded by the proteasome. The VHL tumor
suppressor gene had been cloned, and enormous progress were
made toward the understanding of the molecular biology and
biological function. Over time, germline mutations in VHL
patients, as well as somatic mutations in different tumors, were
identified, and its ability to act as a tumor suppressor in vivo
were confirmed [19]. Several pVHL targets were indicated,
including the members of the hypoxia-inducible factor (HIF)
alpha family [20]. HIF-1alpha and HIF-2alpha, when bound to
a HIF-beta member (such as HIF-1beta), formed a sequence-
specific, DNA-binding transcription factor called HIF.
In this article, we constructed the recombinant plasmid
pBV220-NT4-TAT-6×His-VHLbeta and established a human
RCCmodel of chick embryo chorioallantoic membrane. Next,
plasmid pBV220-NT4-TAT-6×His-VHLbeta was sub-cloned
into the recombinant adeno-associated virus vector. After-
ward, the antitumor effect of the recombinant adeno-
associated virus was investigated on xenografted tumors of
chicken embryo chorioallantoic membrane. Subsequently,
proliferation and apoptotic analyses of transfected cells were
performed to further investigate the antitumor effect of the
recombinant virus by in vitro assay. Finally, associated func-
tional analysis including protein–protein interaction network
and pathway enrichment analysis were performed for VHL
genes, and several interactive genes were identified.
Materials and methods
Materials
The primers (HisF, HisR; VHL F, VHL R) were synthesized
by Shanghai Sangon Co., Ltd. PGEM-T easy carrier and
plasmid kits were purchased from Promega Co., Ltd. Con-
struction of the recombinant plasmid pBV220-NT4 were per-
formed by Xi’an Guanghua Biotechnology (China). The re-
striction endonuclease EcoRI, Eco72I, Nae I and BamHI, T4
DNA ligase, QIAquick Gel Extraction kit, and ethidium bro-
mide were all purchased from Huamei Biotechnology (Chi-
na). Both of the DNAmarker and bovine serum albumin were
purchased from Gibco Corporation. Taq DNA polymerase
and 10 mmol/L dNTP mixed liquor were purchased from
MBI Corporation. The 6×His-Tag antibody was purchased
from Abcam.
RLC-310 cells were maintained in DMEMwith 100 mL/L
fetal calf serum. Fertilized chicken eggs were incubated at
37 °C, relative humidity between 60 and 80 %, air chamber
upward.
Both of propidium iodide and 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased
from Sigma Corporation. SR-50 microplate reader was pur-
chased from Pastur Co., Ltd. FACSan440 flow cytometer was
purchased from Becton Dickinson, USA.
Design and synthesis of the primer
DNA sequences were determined according to literature and
databases [21], including TAT membrane permeability pep-
tide sequence YGRKKRQRRRD, Label peptide sequence
HHHHHH, VHLbeta structure propeptide sequence GTGR
RIHSYRGHLWLFRDAG, and fusion posterior sequence
YGRKKRQRRRD HHHHHH V GTGRRIHSYR
GHLWLFRDAG. The primers were designed according to
nucleotide sequence NM 000551 in gene bank.
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Construction and identification of the recombinant plasmid
pBV220-NT4-TAT-6×His-VHLbeta
Generation and ligation of the recombinant plasmids
were as follows. The fractions were amplified by PCR,
interacting as both primer and template. The first fraction
TAT-6×His was amplified using PCR technique with the
forward primer 5′-C GCCGGCGT TATGGCAGGAAG
AAGCGGAGACAGCGACGA-3′ and the reverse primer
5′-C GGATCCCACGTGATGATGATGATGATG TCT
TCG TCGCTG TC-3′. The second fraction VHLbeta
was amplified by PCR using the forward primer 5′-C
CAC GTGGGCACGGGCCGCCGCATCCACAGCTAC
CGAGGTC and the reverse primer 5′-C GGATCCTC
ACCCTGCATCTCTGAAGAGCCAAAGGT GACCTC
GGT AGC.
PCR reaction mixtures contained 10.0 μL 10× PCR buffer,
2.0 μL dNTP mixture (10.0 mmol/L), 3.0 μL of each primer,
81.0 μL double distilled water, and 50.0 μL paroline was
added at last.
The PCR program included pre-denaturation at 94 °C
for 5 min, 30 amplification cycles each consisting of
denaturation at 94 °C for 1 min after adding 1.0 μL
Taq DNA polymerase, annealing at 31 °C for 1 min
(the second fraction annealing at 35 °C for 1 min), and
extension at 72 °C for 1 min, followed by further exten-
sion at 72 °C for 5 min.
The PCR product were purified and combined to the
vector with T4 DNA ligases. The TAT-6×His PCR prod-
uct was digested with Nae I and BamHI restriction en-
zymes, while the VHLbeta PCR product was digested
with Eco72I and BamHI restriction enzymes. Both of the
DNA fragments after digestion were cloned into plasmid
pGEM-T easy.
Therecombinant plasmid was amplified in Escherichia coli
DH5alpha competent cells using CaCl2 method. NT4-TAT-
6×His-VHLbeta transformants were selected on Luria-
Bertani agar containing ampicillin.
Plasmid preparation was performed by using the alkaline
lysis method [21]. The products were digested with EcoRI and
analyzed by electrophoresis in 10 g/L agarose with staining by
ethidium bromide. Authenticity of all DNA fragments was
confirmed by DNA sequencing.
The recombinant plasmid was identified by the restric-
tion digestion analysis [21]. The plasmids pGEM-T-TAT-
6×His and pGEM-T-VHLbeta were respectively digested
with BamHI and Eco72I restriction enzymes. Afterward,
pGEM-T-TAT-6×His with a cohesive-end and the target
DNA fragment VHLbeta were combined together with
T4 DNA ligases overnight. Then, the recombinant plas-
mid pGEM-T-TAT-6×His-VHLbeta was digested with
EcoRI restriction enzymes, and DNA fragments were
collected for DNA sequencing.
The recombinant plasmid pBV220-NT4-TAT-6×His-
VHLbeta was constructed as follows: The vector pBV220-
NT4 and plasmids pGEM-T-TAT-6×His-VHLbeta comple-
mentary DNA (cDNA) were respectively digested with Nae
I and BamHI. Afterward, the plasmids pBV220-NT4 with a
cohesive-end and the target DNA fragment VHLbeta were
combined together with T4 DNA ligases overnight. Then, the
recombinant plasmid pBV220-NT4-TAT-6×His-VHLbeta
was digested with BamHI and EcoRI, and DNA fragments
was collected for identification of the recombinant plasmids.
Construction of plasmid pBV220-NT4-TAT-6×His-VHLbeta
is shown schematically in Fig. 1.
Establishment of renal cell carcinoma model on chicken
embryos chorioallantoic membrane
Forty chicken embryos incubated for night days were
randomly divided into five groups, with eight embryos
in each group. Before xenografting into chicken embryo
chorioallantoic membrane (CAM), RLC-310 cells were
washed twice with sterile phosphate-buffered saline
(PBS). Then, RLC-310 cell lines in 30-μL PBS at dif-
ferent cell concentration (1.0, 2.0, 4.0, 8.0×106 PFU/
30 μL) were deposited on the avascular zone of the
intact chicken embryo CAM in four groups, respectively.
The last group was defined as the control subject which
inoculated 30-μL PBS. Chicken embryos were sealed
with sterile scotch tape after inoculation.
Tumor growth was monitored 7 days after inoculation
to determine the optimum cell concentration for high
tumor rate. Tumor was regarded as positive when the
diameter was 2 mm or greater. Angiogenesis of the
tumors were observed 5 days after inoculation. After
formaldehyde fixation, paraffin embedding, and section
cutting, the xenografted tumor tissue was observed un-
der a microscope, with a method of hematoxylin–eosin
staining.
Effect of the recombinant adeno-associated virus
on xenografted tumor
The recombinant adeno-associated virus was added to the
chick embryo model. Subsequently, bioactivities of the re-
combinant adeno-associated virus were identified by tumor
suppression assay.
Three days after the inoculation of RLC-310, chicken
embryos with xenografted tumor were divided into three
groups. Group A was administered with 100-μL recom-
binant adeno-associated virus at the concentration of
1.0×109 PFU/100 μL on the xenografted tumors, group
B with 100-μL empty virus at the same concentration,
and group C with 100-μL PBS.
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Five days after the inoculation, the tumor volume was
estimated using the following formula:
V mm3
  ¼ 0:40 a2  b
where V (mm3) is the tumor volume, a (m) is the long
diameter of the tumor, and b (m) is the short diameter of the
tumor.
Expression of the recombinant adeno-associated virus was
confirmed using immunofluorescence with the 6×His-Tag
antibody, labeled by fluorescein isothiocyanate. Cell lines
were stained by immunofluorescence, and detailed informa-
tion of immunofluorescence was described by Gardner and
McQuillin [22] and Fenwick et al. [23]. Changes of the
xenografted tumor were observed through immunofluores-
cence observation. Xenografted tumor was regarded as posi-
tive if cells in experimental groups responded positively in
immunofluorescence tests (++), while those of control subject
did negatively (±or −). After formaldehyde fixation, paraffin
embedding, and section cutting, the xenografted tumor tissue
was observed under a microscope, with a method of hema-
toxylin–eosin staining.
Proliferation and apoptotic analysis of RLC-310 cells
The effect of recombinant adeno-associated virus on RLC-310
cell proliferation was measured by a colorimetric MTT assay.
The proliferation of RLC-310 cells, which induced the inten-
sity of color development was examined by colorimetric
method using microplate reader according to the manufac-
turer’s instructions.
The effect of recombinant adeno-associated virus on
RLC-310 cell apoptosis was analyzed with flow cytom-
etry using flow cytometer. Apoptotic was detected using
staining of the cells with propidium iodide, as described
by Vermes et al. [24]. Detailed information on method
of the proliferation and apoptotic assay is shown in the
supplementary material.
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Protein–protein interaction network construction
Biological modules can be approximately reflected by gene
sets. To identify genes which play a vital role with VHL, the
protein–protein interaction (PPI) network was constructed.
The PPI data were downloaded from Search Tool for the
Retrieval of Interacting Genes/Proteins (STRING) (http://
string.embl.de/). The VHL gene were mapped into the
interaction network, and genes interacted with VHL were
screened. The networks were constructed using Cytoscape
software.
Pathway enrichment analysis
To further investigate the biological functions of these genes,
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway enrichment analysis for modules were performed
by using the online tool Database for Annotation, Visualiza-
tion, and Integrated Discovery (DAVID) [25]. Biological
meaning could be systematically extracted from a large num-
ber of genes or proteins using DAVID bioinformatics re-
sources containing an integrated biological knowledgebase
and analytic tools.
Statistical analysis
The computer-based analysis program SPSS 13.0 was used
for statistical analyses. The rate and volume of the tumors
between different groups was respectively assessed by analy-
sis of χ2 and ‾x ± s. Variance with P<0.05 was regarded as
statistically significant. Comparison between different groups
was assessed by least significant difference. The EASE score
was used to detect the significant categories in the functional
enrichment and pathway enrichment analysis [26]. The
threshold of EASE score <0.01 and the minimum number of
genes for the corresponding term >2 were considered signif-
icant for a category.
Results
Construction and identification of the recombinant plasmid
pBV220-NT4-TAT-6×His-VHLbeta
The expected length of NT4-TAT-6, VHLbeta cDNA, and the
EcoRI digested pGEM-T fragment were 69, 75, and 3,015 bp,
respectively. The agarose gel electrophoresis analysis showed
that after BamHI-Eco72I double digestion, both of the NT4-
TAT-6-digested fragment and the VHLbeta-digested fragment
left were nomore than 100 bp (Fig. 2a).Moreover, the agarose
gel electrophoresis analysis of the digested fragments from
both of pGEM-T-TAT-6×His and pGEM-T-VHLbeta cDNA
also showed the consistent length as expected (Fig. 2b).
The inserted fragments with target gene (132 bp) from
recombinant plasmid pGEM-T were verified by agarose gel.
The VHLbeta cDNAwas successfully inserted into pGEM-T-
TAT-6×His plasmid identified by BamHI digestion (Fig. 2c),
while the partial sequencing analysis showed the TAT-6×His-
VHLbeta cDNAwere consistent with the sequences as report-
ed by Datta et al. [27] (Fig. 2d).
The NT4-TAT-6×His-VHLbeta cDNA (363 bp) from re-
combinant plasmid pBV220-NT4-TAT-6×His-VHLbeta was
also verified by agarose gel. The VHLbeta cDNA was suc-
cessfully inserted into pBV220-NT4-TAT-6×His-VHLbeta
plasmid (Fig. 2e), identified by EcoRI and BamHI double
digestion (3,666 bp) and EcoRI digestion (4,029 bp).
Establishment of renal cell carcinoma model on chicken
embryos chorioallantoic membrane
Inoculation of RLC-310 cell lines on the chick embryos
resulted in the development of large tumors. Table 1 showed
a strong relationship between tumor rate and RLC-310 cell
concentration on the seventh day after inoculation. The more
cell concentration it inoculated, the higher tumor rate goes.
Comparison was conducted with the analysis of variance,
which showed significant difference between each group
(P<0.05).
Group B showed significant difference compared with
group D and E (P<0.05), while there were no significant
difference between group E and group D (P>0.05), although
the tumor rate of group E was higher than group D.
The tumor, with an average diameter of 6 mm, exhibited an
ivory-white appearance on the surface and integrated into the
mass of the CAM. CAM of the control group showed no
significant change after inoculation.
On the fifth day after inoculation, the blood vessel distrib-
uted in and around the xenografted tumor (Fig. 3a), while
blood vessel of the control group, which exhibited a very
smooth surface in a form of arborization, showed no signifi-
cant change after inoculation (Fig. 3b).
On the seventh day after inoculation, the chicken embryos
showed cyst formation and focal necrosis. The cancer cells
showed a diversity arrangement and various appearances,
which adopted a bulky and polygonal shape (Fig. 3c, d).
Effect of the recombinant adeno-associated virus
on xenografted tumor
Photographs of xenografted tumors are shown in
Fig. 4a–c. Blood vessel in each group were radiating
outward in the tumor. Tumors in group A showed un-
sharp images, while those in group B and group C were
concentrated and clearly visible.
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Comparison was conducted with the analysis of variance,
which showed significant difference between each group (F=
4.72, P<0.05). The tumor volumes of group Awas significantly
reduced when compared with group B and group C (P<0.05).
Although the tumor volume of group C was greater than that of
group B, there were no significant differences between them
(P>0.05). The tumor volumes are shown in Fig. 3e.
Immunofluorescence images of xenografted tumors
are shown in Fig. 4d–f. Bright fluorescent appeared in
group A (++), while no fluorescence was found in
group B and group C (−).
Microscope images of xenografted tumors are shown in
Fig. 4g–i. In the epithelial tissue of chick embryos in group A,
tumor mass and tissue around seemed to dissect into separate
areas with the spontaneous percept of distinct borders between
them.
Proliferation and apoptotic analysis of RLC-310 cells
The effect of recombinant virus on proliferation of RLC-310
cells is shown in Fig. S1. The proliferation of RLC-310 cells
that administered with recombinant virus was significantly
restrained compared to the two control groups.
The effect of recombinant virus on apoptosis of RLC-310
cells is shown in Fig. S2. The apoptotic rate of RLC-310 cells
that administered with recombinant virus was significantly
raised compared to the two control groups (detailed informa-
tion on result of the proliferation and apoptotic assay is shown
in the supplementary material).
Fig. 2 Validation of the recombinant plasmid pBV220-NT4-TAT-6×
His-VHLbeta. aValidation of PCR products of TAT-6×His and VHLbeta
cDNA; DNA marker (M); PCR product of TAT-6×His (a); PCR product
of VHLbeta cDNA (b). b Validation of recombinant plasmid pGEM-T-
TAT-6×His and pGEM-T-VHLbeta by restriction enzyme digestion;
DNAmarker (M); pGEM-T-TAT-6×His (a); pGEM-T-TAT-6×His/EcoRI
(b); pGEM-T-VHLbeta/EcoRI (c); pGEM-T-VHLbeta (d). cValidation of
recombinant plasmid pGEM-T-TAT-6×His-VHLbeta by restriction
enzyme digestion; DNA marker (M); pGEM-T-TAT-6×His-VHLbeta/
Nae I+BamHI (3,015+132 bp) (a); pGEM-T-TAT-6×His-VHLbeta
(without enzyme digestion) (b). d Partial sequencing of recombinant
plasmid pGEM-T-TAT-6×His-VHLbeta. e Validation of recombinant
plasmid pBV220-NT4-TAT-6×His-VHLbeta by restriction enzyme di-
gestion; DNA marker (M); pBV220-NT4-TAT-6×His-VHLbeta (a);
pBV220-NT4-TAT-6×His-VHLbeta/EcoRI+BamHI (3,666+363 bp)
(b); pBV220-NT4-TAT-6×His-VHLbeta/EcoRI (4,029 bp) (c)






A 0 8 0 (0)
B 1 8 1 (12.5)
C 2 8 3 (37.5)
D 4 8 7 (87.5)
E 8 8 8 (100)
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Fig. 3 Evaluation of xenografted
tumors on CAM. a A photograph
of the xenografted tumor on the
fifth day after inoculation. b A
photograph of blood vessels of
the control group on the fifth day
after inoculation. cAmicroscopic
evaluation of the xenografted
tumor (HE, ×100). d A
microscopic evaluation of the
xenografted tumor (HE, ×200). e
Volume of the xenografted tumor
in each group (mm3); chick
embryos administered with
rAAV/NT4-TAT-6×His-
VHLbeta (a); empty virus (b);
control (c)
Fig. 4 Evaluation of xenografted
tumors administered with
different reagents. a A
photograph of the xenografted
tumor administered with
rAAV/NT4-TAT-6×His-
VHLbeta. b A photograph of the
xenografted tumor administered
with empty virus. c A photograph
of the xenografted tumor of the
control group. d An
immunofluorescence evaluation




evaluation of the xenografted
tumor administered with empty
virus (×100). f An
immunofluorescence evaluation
of the xenografted tumor of the
control group (×100). g A
microscopic evaluation of the
xenografted tumor administered
with rAAV/NT4-TAT-6×His-
VHLbeta (HE, ×200). h A
microscopic evaluation of the
xenografted tumor administered
with empty virus (HE, ×200). i A
microscopic evaluation of the
xenografted tumor of the control
group (HE, ×200)
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Protein–protein interaction network construction
To obtain a PPI network, the relationship of proteins encoded
by 170 genes associated to VHL were matched according to
the PPI database. By integrating interaction relationships, a
PPI network was constructed (Fig. 5). Genes at the top of
degree distribution in the significantly perturbed networks
were defined as hub genes. Hub genes with degree equal or
greater than three in the PPI network are shown in Table 2.
Among the nodes in perturbed networks, we found night hub
genes with the highest degree of structural disorder: EPAS1,
TCEB2, HIF1A, TCEB1, HDAC2, CUL2, EGLN2, RBX1,
and PHF17.
Pathway enrichment analysis
Pathway enrichment analyses were carried out for these genes.
Results showed that 170 genes in PPI network were signifi-
cantly enriched in seven pathways (Table 3). The most signif-
icant signaling pathway was renal cell carcinoma (P=
0.81511671), which is shown in Fig. 6. Genes such as
TCEB2, HIF1A, TCEB1, CUL2, and RBX1 were involved
in both of the first and the third routes of the renal cell
carcinoma pathway. Both of the molecular interaction and
the missing interaction were expressed, suggesting that these
two routes were activated in the RCC process.
Discussion
In this study, we established a stable and highly effective
method of delivering gene construct containing VHL cDNA
into RLC-310 cells as a way of attaining continuous VHL
production. Recombinant adeno-associated virus was assem-
bled to achieve this goal. The antitumor effect of the recom-
binant adeno-associated virus on RCC was demonstrated.
Xenografted tumors as well as transfected cells which admin-
istered with the recombinant adeno-associated virus resulted
in growth inhibition, indicating that the adeno-associated virus
might be used as a gene-therapeutic agent for the treatment of
RCC.
In addition, we found a series of hub genes involved in PPI
network which interacted with VHL and predicted the statis-
tically significant KEGG pathway of renal cell carcinoma.
Moreover, the significance of those indicated hub genes in
the present study was further confirmed by the significant
signaling pathway of RCC. As shown in Fig. 6, TCEB2,
HIF1A, TCEB1, CUL2, and RBX1were involved in the renal
cell carcinoma pathway, while TCEB2, HIF1A, TCEB1, and
CUL2 had the highest degree in the PPI network. This sug-
gested that those indicated hub genes might be highly
related to the development of RCC. All these results
indicated that TCEB2, HIF1A, TCEB1, and CUL2
might be related with RCC. In addition, the influence
of HIF1A [28–31], TCEB1 [32], CUL2 [33], and
PHF17 [34] on development of RCC had been reported,
which verified the inference above.
The pVHL complex has the ability to ubiquitinate proteins
which can then mark these proteins for subsequent degrada-
tion by the proteasomal machinery of the cell [13, 35]. This
ubiquitin ligase activity was one of the critical mechanisms by
which the cell regulated the protein level of key regulatory
Fig. 5 The PPI network consisting of 170 genes related to VHL (VHL is
the central node). The pertinent interaction is between the central node
and the edges. Types of edge lines which stand for different detection
methods are shown in the figure
Table 2 The genes that
degree equal or greater
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molecules in the cell, such as HIF1-alpha [36]. Hypoxia
inducible factor 1 (HIF-1) was a key regulator of the genes
involved in the cellular response to hypoxia [37]. It was
subsequently demonstrated that this occurred through the
oxygen-dependent polyubiquitination and subsequent degra-
dation of HIF-alpha that was critically mediated and regulated
by the VHL protein [29–31, 38]. The VHL and HIF1-alpha
polymorphisms might jointly influence RCC progression and
survival [28].
Sequences outside the TCEB1 binding box might function
as a nuclear export domain, potentially providing a novel role
for this region of VHL frequently mutated in RCC.
Inactivating mutations of the VHL tumor suppressor gene
caused the VHL cancer syndrome and sporadic ccRCC [32].
Table 3 The pathways analysis based on KEGG
Term P value Genes
hsa05211:Renal cell carcinoma 2.61E−21 MAP2K1, EPAS1, VHL, ARNT2, MET, EGLN3, EGLN2, EGLN1, HGF, FLCN, ARNT,
RBX1, CUL2, EP300, HIF1A, VEGFA, GAB1, SLC2A1, TCEB2, TGFA, TCEB1, FH
hsa05200:Pathways in cancer 6.05E−13 MMP9, ARNT2, EGLN3, EGLN2, KITLG, EGLN1, MMP2, ARNT, RBX1, CUL2, SLC2A1,
TGFA, FH, FN1, RET, COL4A2, EPAS1, MAP2K1, VHL, MET, TP53, HGF, HIF1A,
HDAC2, EP300, VEGFA, TCEB2, MTOR, TCEB1
hsa04120:Ubiquitin mediated
proteolysis
6.21E−07 VHL, BTRC, CDC34, PARK2, SKP1, RBX1, CUL2, CUL5, TCEB2, SIAH1, TCEB1, ITCH,
UBE2S, CUL1
hsa04510:Focal adhesion 0.002691788 COL4A2, FLT1, MAP2K1, ITGB8, MET, VEGFA, ITGB5, HGF, FLNA, KDR, FN1
hsa05016:Huntington’s disease 0.004264142 SDHB, POLR2G, POLR2F, EP300, HDAC2, SP1, SDHC, SDHD, TP53, POLR2A
hsa04060:Cytokine–cytokine
receptor interaction
0.00610182 FLT1, CXCR4, CXCL13, MET, VEGFA, KITLG, EPOR, HGF, CXCL12, CCL27, KDR, EPO
hsa05219:Bladder cancer 0.006148358 MAP2K1, MMP9, VEGFA, TP53, MMP2
Fig. 6 The KEGG pathway of renal cell carcinoma consisting of 170 genes related to VHL. Both of the first and the third routes of renal cell carcinoma
pathway are activated. Notation of the pathway map is shown in the figure
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In addition, defective VHL-mediated proteolysis as a common
feature of ccRCC was caused not only by VHL inactivation
but also by new hotspot TCEB1 mutations, which abolished
TCEB1–VHL binding, leading to HIF accumulation [39].
As binding of the VHL gene product to the CUL2 protein is
important for pVHL function, germline CUL2 mutations were
searched. Although no pathogenic mutations were detected,
CUL2 polymorphisms were identified [33]. A model for the
regulation of hypoxia-inducible mRNAs by pVHL was re-
spectively presented based on the apparent similarity of
TCEB1 and Cul2 to Skp1 and Cdc53. These latter proteins
formed complexes that target specific proteins for ubiquitin-
dependent proteolysis [40], suggesting that CUL2 takes part
in the development of RCC.
PHF17 could suppress RCC in part by increasing apopto-
sis. Most renal cancers had defects in the VHL tumor sup-
pressor pVHL. PHF17 was a short-lived, kidney-enriched
transcription factor that was stabilized by direct interaction
with pVHL. Loss of PHF17 stabilization with pVHL corre-
lated with renal cancer risk, suggesting the relationship be-
tween PHF17 and renal cancer. In addition, PHF17 was a
candidate transcriptional co-activator which might play a
key role in the pathogenesis of renal cancer and VHL disease
[34]. In conclusion, PHF17 was identified as a protein partner
of the VHL tumor suppressor pVHL.
The CAM assay was well established and widely used
as a model for tumor angiogenesis and invasiveness. In
1976, Knighton et al. [41] first implanted carcinosarcoma
on the chrioallantoic membrane. Currently, CAM has
been used in research involving angiogenesis, microcir-
culation, oncobiology, etc [42]. In this article, we
established a human RCC model on CAM, and the
antitumor effect of the recombinant adeno-associated vi-
rus had been demonstrated experimentally on CAM
xenografted tumor. Major findings developed from the
CAM agents were accomplished.
The minigene anticancer therapy with the application of
the recombinant adeno-associated virus will be used in the
clinic. However, further validation is required to elucidate
the expression of hub gene in protein or RNA level that
involved in development of renal cell carcinoma. Further-
more, the security and specificity of the recombinant
adeno-associated virus is to be determined. Therefore, such
gene therapy would still be far from clinical use.
Conclusion
In this paper, we constructed and identified the recombinant
adeno-associated virus NT4-TAT-6×His-VHLbeta and re-
vealed the relevant biological function related to RCC. Based
on the network analyses, we identified a series of hub genes
which might be involved in the development of RCC.
Transfection of recombinant virus in RLC-310 cells strongly
restrained cell proliferation and markedly induced apoptosis.
Genes of TCEB2, HIF1A, TCEB1, and CUL2 which partic-
ipated in renal cell carcinoma pathway might be the potential
target genes for RCC treatment.
The results of this study demonstrated the feasibility of the
recombinant adeno-associated virus with VHL gene, also
suggesting that such a construct may provide the basis for
future clinical applications in treatment of RCC.
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